1. Immunology/Inflammation PI3K/Akt/mTOR
  2. Transmembrane Glycoprotein Akt mTOR
  3. JM1-24-3

JM1-24-3 is an anti-MUC18 mouse monoclonal antibody with a Kd value of 1.60e-9 M. JM1-24-3 reduces the phosphorylation levels of p-AKT (Ser473) and p-mTOR (Ser2448) in a time-dependent manner. JM1-24-3 exhibits anticancer activity against melanoma. JM1-24-3 can be used in studies related to metastatic melanoma.

For research use only. We do not sell to patients.

JM1-24-3

JM1-24-3 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

View All Akt Isoform Specific Products:

View All mTOR Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

JM1-24-3 is an anti-MUC18 mouse monoclonal antibody with a Kd value of 1.60e-9 M. JM1-24-3 reduces the phosphorylation levels of p-AKT (Ser473) and p-mTOR (Ser2448) in a time-dependent manner. JM1-24-3 exhibits anticancer activity against melanoma. JM1-24-3 can be used in studies related to metastatic melanoma[1][2].

Species Reactivity

Human

In Vitro

JM1-24-3 (0.001-10 μg/mL) binds dose-dependently to live A375, A2058, and WM266-4 melanoma cells, with significantly stronger binding to highly metastatic A2058 and WM266-4 cells than to low metastatic A375 cells[1].
JM1-24-3 (0.001-10 μg/mL) binds dose-dependently to A375, A2058, and WM266-4 melanoma cell lysates, with significantly stronger binding to highly metastatic A2058 cell lysates than to WM266-4 or low metastatic A375 cell lysates[1].
JM1-24-3 binds to recombinant MUC18 with a high affinity (KD = 1.60E-09)[1].
JM1-24-3 (0.001-1 μg/mL) binding to WM266-4 melanoma cells is partially dependent on N-linked glycosylation of MUC18, as tunicamycin treatment (3.0 μg/mL; 24 h) reduces binding by 40.7%[1].
JM1-24-3 (1 h, 6 h for RPPA; 0.5-24 h for WB) binding to MUC18 on WM266-4 melanoma cells modulates downstream signaling pathways, including time-dependent reduction of p-AKT (Ser473) and p-mTOR (Ser2448) phosphorylation, and alters expression of key cancer-associated proteins[1].
JM1-24-3 (150 μg/mL; 7 days) inhibits proliferation of A375, A2058, and WM266-4 melanoma cells by 52%, 76%, and 46% respectively after 7 days of incubation[1].
JM1-24-3 (150 μg/mL; 24 h) inhibits migration of WM266-4 melanoma cells by 58% after 24 h of incubation[1].
JM1-24-3 (150 μg/mL) inhibits invasion of WM266-4 melanoma cells by 52%[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: A375, A2058, WM266-4
Concentration: 150 μg/mL
Incubation Time: 7 days
Result: Significantly inhibited proliferation of all three cell lines: A375 by 52%, A2058 by 76%, and WM266-4 by 46% (p < 0.01 for all) compared to irrelevant mAb treatment.

Cell Migration Assay [1]

Cell Line: WM266-4
Concentration: 150 μg/mL
Incubation Time: 24 h
Result: Significantly reduced WM266-4 cell migration by 58% (p < 0.01) compared to irrelevant mAb treatment.
In Vivo

JM1-24-3 (6 mg/kg; i.p.; twice weekly; for 45 days) significantly reduces the volume of subcutaneous melanoma xenografts, with no observed toxicity[1].
JM1-24-3 (6 mg/kg; i.p.; twice weekly; administered 1 day prior to tumor cell injection and continued until day 45) significantly reduces the average number of melanoma lung metastases to 3.8 colonies per mouse[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Athymic nude (nu/nu) (male, 4-8 weeks old, subcutaneous xenograft model via injection of 1 million WM266-4 melanoma cells)[1]
Dosage: 6 mg/kg
Administration: i.p.; twice a week; 45 days
Result: Reduced tumor volume to 46.8 mm3 (p < 0.01).
Caused no observable toxicity, including no reduction in body weight.
Gene ID

4162  [NCBI]

Accession
Target

MUC18/MCAM/CD146

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
JM1-24-3
Cat. No.:
HY-P992392
Quantity:
MCE Japan Authorized Agent: